# Qianren Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qianren-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Lianyungang, China
- Website: www.qianrenpharm.com
- Total disclosed funding: $14M
- Latest round: Series A (Dec 8, 2025)
- Investors on record: 2

## About

Based in Lianyungang, China, and founded in 2016, Jiangsu Qianren Biotechnology Co., Ltd., doing business as Qianren Pharmaceutical, is a pharmaceutical company integrating research, development, production and sales. To date, the company employs over 200 people, including more than 100 people working in R&D. It has established a drug research center and collaborates with renowned domestic universities and research institutes in China.

In December 2025, Qianren Pharmaceutical raised an undisclosed amount of series A+ funding from returning investor Jiangsu Jinqiao Private Equity Fund Management.

Qianren Pharmaceutical mainly engages in the research, development, production, and sales of cardiovascular, respiratory, digestive, anti-tumor, and anti-diabetic drugs. The company's main products include Sitagliptin Metformin Extended-Release Tablets, Eperisone Hydrochloride Tablets, Mesalazine Enteric-Coated Tablets, etc. The company generates revenues from providing pharmaceutical products.

The series A+ funding will be used by the company to advance the clinical development of ongoing projects and to build the technology research and development platform.

## Funding rounds

- Series A, Dec 8, 2025 — Jiangsu Jinqiao Private Equity Fund Management
- Series A, Jan 9, 2024, $14M — Jiangsu Jinqiao Private Equity Fund Management, Shanghe Zuzhi Fund

## Investors

- Jiangsu Jinqiao Private Equity Fund Management (https://capitalatlas.ai/funds/jiangsu-jinqiao-private-equity-fund-management) — Series A
- Shanghe Zuzhi Fund — Series A